TREATMENT UNDERSTANDING THE ORAL OR GASTRIC ADMINISTRATION OF EDARAVONE

摘要

the invention relates to a liquid pharmaceutical composition for use in medical treatment, said liquid pharmaceutical composition comprising a monophasic aqueous solution of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) and comprising at least 75% by weight of water and 0.2-9 mg / ml of edaravone, wherein the treatment comprises the oral or gastric administration of 10-250 ml of the liquid pharmaceutical composition to provide 30-300 mg of edaravone.